[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 1,059
Citations 0
From The Medical Letter on Drugs and Therapeutics
November 24, 2015

VEGF Inhibitors for AMD and Diabetic Macular Edema

JAMA. 2015;314(20):2184-2185. doi:10.1001/jama.2015.15427

Vascular endothelial growth factor (VEGF) is a principal mediator of neovascularization in wet age-related macular degeneration (AMD) and diabetic macular edema. It induces angiogenesis and increases vascular permeability and inflammation. VEGF inhibitors reduce leakage from blood vessels, prevent proliferation of new abnormal vessels, decrease swelling of the retina, and improve visual acuity in patients with neovascular (wet) AMD and diabetic macular edema.1,2 These drugs are given as periodic intravitreal injections with topical anesthesia (Table).

First Page Preview View Large
First page PDF preview
First page PDF preview